The use of rituximab in the treatment of disimmune polyneuropathy: a description of clinical cases and a literature review

Dysimmune neuropathies are heterogeneous group of acquired immune-mediated diseases, accompanied by damage to the peripheral nervous system. As a standard therapy, prednisolone and intravenous immunoglobulins are used. Also encouraging efficacy is demonstrated by the use of a genetically engineered...

Full description

Saved in:
Bibliographic Details
Main Authors: V. N. Kiselev, V. G. Potapenko
Format: Article
Language:Russian
Published: ABV-press 2019-07-01
Series:Нервно-мышечные болезни
Subjects:
Online Access:https://nmb.abvpress.ru/jour/article/view/327
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849399736287625216
author V. N. Kiselev
V. G. Potapenko
author_facet V. N. Kiselev
V. G. Potapenko
author_sort V. N. Kiselev
collection DOAJ
description Dysimmune neuropathies are heterogeneous group of acquired immune-mediated diseases, accompanied by damage to the peripheral nervous system. As a standard therapy, prednisolone and intravenous immunoglobulins are used. Also encouraging efficacy is demonstrated by the use of a genetically engineered chimeric monoclonal antibody to the CD20 antigen found on the surface of normal and malignant B-cells – rituximab. Rituximab shows encouraging results. We reviewed the use of rituximab for dysimmune polyneuropathies and described our experience in administration of Lewis–Sumner syndrome and myelin-associated glycoprotein related neuropathy with rituximab.
format Article
id doaj-art-fd14c6c08ea045ceadb4071c9d4a1e94
institution Kabale University
issn 2222-8721
2413-0443
language Russian
publishDate 2019-07-01
publisher ABV-press
record_format Article
series Нервно-мышечные болезни
spelling doaj-art-fd14c6c08ea045ceadb4071c9d4a1e942025-08-20T03:38:15ZrusABV-pressНервно-мышечные болезни2222-87212413-04432019-07-0192505810.17650/2222-8721-2019-9-2-50-58241The use of rituximab in the treatment of disimmune polyneuropathy: a description of clinical cases and a literature reviewV. N. Kiselev0V. G. Potapenko1Russian national Center for Emergency and Radiation Medicine n. a. A. M. NikiforovaCity Clinical Hospital № 31Dysimmune neuropathies are heterogeneous group of acquired immune-mediated diseases, accompanied by damage to the peripheral nervous system. As a standard therapy, prednisolone and intravenous immunoglobulins are used. Also encouraging efficacy is demonstrated by the use of a genetically engineered chimeric monoclonal antibody to the CD20 antigen found on the surface of normal and malignant B-cells – rituximab. Rituximab shows encouraging results. We reviewed the use of rituximab for dysimmune polyneuropathies and described our experience in administration of Lewis–Sumner syndrome and myelin-associated glycoprotein related neuropathy with rituximab.https://nmb.abvpress.ru/jour/article/view/327dysimmune polyneuropathychronic inflammatory demyelinating polyneuropathylewis–sumner syndromeparaproteinmyelin-associated glycoproteinmyelin-associated antibodiesglycoproteinrituximab
spellingShingle V. N. Kiselev
V. G. Potapenko
The use of rituximab in the treatment of disimmune polyneuropathy: a description of clinical cases and a literature review
Нервно-мышечные болезни
dysimmune polyneuropathy
chronic inflammatory demyelinating polyneuropathy
lewis–sumner syndrome
paraprotein
myelin-associated glycoprotein
myelin-associated antibodies
glycoprotein
rituximab
title The use of rituximab in the treatment of disimmune polyneuropathy: a description of clinical cases and a literature review
title_full The use of rituximab in the treatment of disimmune polyneuropathy: a description of clinical cases and a literature review
title_fullStr The use of rituximab in the treatment of disimmune polyneuropathy: a description of clinical cases and a literature review
title_full_unstemmed The use of rituximab in the treatment of disimmune polyneuropathy: a description of clinical cases and a literature review
title_short The use of rituximab in the treatment of disimmune polyneuropathy: a description of clinical cases and a literature review
title_sort use of rituximab in the treatment of disimmune polyneuropathy a description of clinical cases and a literature review
topic dysimmune polyneuropathy
chronic inflammatory demyelinating polyneuropathy
lewis–sumner syndrome
paraprotein
myelin-associated glycoprotein
myelin-associated antibodies
glycoprotein
rituximab
url https://nmb.abvpress.ru/jour/article/view/327
work_keys_str_mv AT vnkiselev theuseofrituximabinthetreatmentofdisimmunepolyneuropathyadescriptionofclinicalcasesandaliteraturereview
AT vgpotapenko theuseofrituximabinthetreatmentofdisimmunepolyneuropathyadescriptionofclinicalcasesandaliteraturereview
AT vnkiselev useofrituximabinthetreatmentofdisimmunepolyneuropathyadescriptionofclinicalcasesandaliteraturereview
AT vgpotapenko useofrituximabinthetreatmentofdisimmunepolyneuropathyadescriptionofclinicalcasesandaliteraturereview